This material is an English translation of the press release announced on January 19, 2018 in Japanese, and the Japanese release is given priority about the content and the interpretation.

January 19, 2018

Notification of the approval of a manufacturing and marketing for ALLESAGA® TAPE (Development Code: HP-3060) in Japan, a transdermal system for the treatment of allergic rhinitis.

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) announces that it has been approved for manufacturing and marketing for a transdermal drug product for the treatment of allergic rhinitis, ALLESAGA® TAPE 4 mg and ALLESAGA® TAPE 8 mg (Active pharmaceutical ingredient: emedastine fumarate, hereinafter referred to as "the product") in Japan as of today.

The product is a systemic transdermal tape formulation developing by utilizing Hisamitsu's TDDS (Transdermal Drug Delivery System) technology. It is expected that the product has a long-lasting effect by means of maintaining a stable blood drug concentration.

Hisamitsu will contribute to the improvement in the quality of life of patients who suffer from allergic rhinitis by providing proper information of the product.

Reference:

Trade name	ALLESAGA® TAPE 4 mg ALLESAGA® TAPE 8 mg
Active pharmaceutical ingredient	Emedastine fumarate
Indication	Allergic rhinitis
Dosage and Administration	Usually apply 4 mg formulation (as emedastine fumarate) per once on the chest, upper arm, back or abdomen of an adult and replace every 24 hours. Further, according to the symptoms, the dosage can be increased to 8 mg.
Size of formulation	8 cm^2 (ALLESAGA® TAPE 4 mg) 16 cm^2 (ALLESAGA® TAPE 8 mg)